Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.32 |
| ▸ | PTP4A2 | Q12974 | 1/20 | 0.32 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7157164 | 1.00 | MAPT (0.38) | MAPTTSHRCACNA1BAPBA1CYP3A4 | |
| SCHEMBL3962674 | 0.79 | MAPT (0.42) | MAPTTSHRCACNA1BAPBA1CYP3A4 | |
| SCHEMBL175302 | 0.75 | TSHR (0.40) | MAPTTSHRCACNA1BAPBA1CYP3A4 | |
| SCHEMBL177943 | 0.75 | CYP3A4 (0.48) | MAPTTSHRCACNA1BAPBA1CYP3A4 | |
| SCHEMBL9521695 | 0.73 | HCAR2 (0.39) | TSHRTDP1ALDH1A1LMNAMAPK1 | |
| SCHEMBL9521700 | 0.73 | HCAR2 (0.39) | TSHRTDP1ALDH1A1LMNAMAPK1 | |
| SCHEMBL15137029 | 0.73 | MAPT (0.39) | MAPTTSHRCACNA1BAPBA1CYP3A4 | |
| SCHEMBL288622 | 0.73 | ALDH1A1 (0.39) | MAPTTSHRCACNA1BAPBA1CYP3A4 | |
| SCHEMBL7512684 | 0.73 | CYP3A4 (0.46) | MAPTTSHRCACNA1BAPBA1CYP3A4 | |
| SCHEMBL6168638 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620932-B2 | 2-alkoxy group may be introduced into the appropriate pyrimidine derivatives at the start of the reaction | DEGUSSA AG (DE) | 2003-09-16 | — | — | US | claimed |
| US-20030022908-A1 | 2-alkoxy-5-methoxypyrimidines or their tautomeric forms and methods for producing the same | DEGUSSA AG (DE) | 2003-01-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022908-A1 | 2-alkoxy-5-methoxypyrimidines or their tautomeric forms and methods for producing the same | DPYD, TYMP, UMPS | MAPT 59/4885TSHR 4534/4885CACNA1B 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.